Atkinson Thomas Prescott, Balish Mitchell F, Waites Ken B
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
FEMS Microbiol Rev. 2008 Nov;32(6):956-73. doi: 10.1111/j.1574-6976.2008.00129.x. Epub 2008 Aug 27.
Since its initial description in the 1940s and eventual elucidation as a highly evolved pathogenic bacterium, Mycoplasma pneumoniae has come to be recognized as a worldwide cause of primary atypical pneumonia. Beyond its ability to cause severe lower respiratory illness and milder upper respiratory symptoms it has become apparent that a wide array of extrapulmonary infectious and postinfectious events may accompany the infections in humans caused by this organism. Autoimmune disorders and chronic diseases such as asthma and arthritis are increasingly being associated with this mycoplasma, which frequently persists in individuals for prolonged periods. The reductive evolutionary process that has led to the minimal genome of M. pneumoniae suggests that it exists as a highly specialized parasitic bacterium capable of residing in an intracellular state within the respiratory tissues, occasionally emerging to produce symptoms. This review includes discussion of some of the newer aspects of our knowledge on this pathogen, characteristics of clinical infections, how it causes disease, the recent emergence of macrolide resistance, and the status of laboratory diagnostic methods.
自20世纪40年代首次被描述并最终被确认为一种高度进化的致病细菌以来,肺炎支原体已成为全球原发性非典型肺炎的病因。除了能够引起严重的下呼吸道疾病和较轻的上呼吸道症状外,很明显,由这种生物体引起的人类感染可能伴随着一系列广泛的肺外感染和感染后事件。自身免疫性疾病和慢性疾病,如哮喘和关节炎,越来越多地与这种支原体相关联,这种支原体经常在个体中长期存在。导致肺炎支原体基因组最小化的简化进化过程表明,它作为一种高度专业化的寄生细菌存在,能够在呼吸组织内以细胞内状态存在,偶尔出现并产生症状。本综述包括对我们关于这种病原体的一些新知识的讨论,临床感染的特征,它如何引起疾病,大环内酯耐药性的最近出现,以及实验室诊断方法的现状。